Oncology Micro learning - Video, slides and more 

The Use of Immunotherapy in HCC

Module 1: Efficacy and Safety

Prof. Dr Peter R. Galle

Prof. Dr Peter R. Galle
Prof. Aiwu Ruth He

Prof. Aiwu Ruth He
Publication Date

Apr 2023

info Summary and next episodes download Downloadable resources

In Module 1 of this micro learning, developed by experts Prof. Peter R. Galle and Dr Aiwu Ruth He, you'll learn about the safety and efficacy of immunotherapy (IO) for hepatocellular carcinoma (HCC) and how to implement IO treatments for patients with HCC in clinical practice.

The content includes a short animated video, downloadable resources, and an assessment to test your knowledge.

When you're ready, move on to Module 2: The Use of Immunotherapy in HCC: In-depth Subgroup Analyses and Challenges.

 

Efficacy of IO for HCC

Learn how to:

  • Recognise the efficacy of IO and IO combinations
  • Understand the survival curve when assessing IO treatment
  • Know where IO and IO combinations sit in the treatment landscape for patients with HCC

 

Safety of IO for HCC

Learn how to:

  • Recognise the immune-related adverse events (irAEs) and potential additive or synergistic toxicities associated with IO combinations
  • Know how to identify and manage these AEs early on

 

Clinical Takeaways

 

  • IO, and in particular IO combinations, are effective treatments for patients with advanced HCC

  • Survival analysis for IO treatment shifts from median overall survival (OS) to landmark analysis

  • IO and IO combinations may result in inflammatory side effects, known as irAEs. Most of these AEs can be treated with steroids

  • Recognise the efficacy of IO and IO combinations 
    • Understand the survival curve when assessing IO treatment 
    • Know the place of IO and IO combinations in the treatment landscape for patients with HCC 
  • Recognise the immune-related adverse events (irAEs), and potential additive or synergistic toxicities associated with IO combinations 
    • Know how to early identify and manage these AEs 
  • Be able to implement IO treatments for patients with HCC in clinical practice 

Aiwu Ruth He, MD, PhD is a Professor of Medicine at Columbia University Medical Center. She earned her MD from the Xiangya School of Medicine at Central South University and her PhD in Biochemistry from East Carolina University’s Brody School of Medicine. Dr He completed her postdoctoral training at the National Institutes of Health under the mentorship of Dr Simeon Taylor, followed by an internal medicine residency at the Brody School of Medicine and a Hematology/Oncology fellowship at Georgetown University Hospital.

 

Dr He is a recognized leader in liver cancer research and patient care, with a primary focus on developing innovative therapeutics for hepatocellular carcinoma (HCC) and biliary tract cancer (BTC). 

 

She is deeply committed to a programmatic, multidisciplinary approach to clinical practice, ensuring optimal outcomes for her patients across the continuum of care.

 

Outside of her clinical duties, Dr He serves as the Director of Hepatobiliary Cancers in the Department of Medicine, Division of Hematology and Oncology, as well as the Director of Liver Transplant Oncology at the Center for Liver Disease and Transplantation. In these roles, she oversees clinical research on hepatobiliary cancers.

 

For a list of publications, please visit:

https://pubmed.ncbi.nlm.nih.gov/?term=he%2C+AR+or+He%2C+aiwu

Prof. Aiwu Ruth He has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, BMS, Boston Scientific, Eisai, Genentech and Merck.
pdf Flashcard - pdf Download clock
pdf Slides - pdf Download clock
pdf Slides - PPT Download clock

In Module 1 of this micro learning, developed by experts Prof. Peter R. Galle and Dr Aiwu Ruth He, you'll learn about the safety and efficacy of immunotherapy (IO) for hepatocellular carcinoma (HCC) and how to implement IO treatments for patients with HCC in clinical practice.

The content includes a short animated video, downloadable resources, and an assessment to test your knowledge.

When you're ready, move on to Module 2: The Use of Immunotherapy in HCC: In-depth Subgroup Analyses and Challenges.

 

Efficacy of IO for HCC

Learn how to:

  • Recognise the efficacy of IO and IO combinations
  • Understand the survival curve when assessing IO treatment
  • Know where IO and IO combinations sit in the treatment landscape for patients with HCC

 

Safety of IO for HCC

Learn how to:

  • Recognise the immune-related adverse events (irAEs) and potential additive or synergistic toxicities associated with IO combinations
  • Know how to identify and manage these AEs early on

 

Clinical Takeaways

 

  • IO, and in particular IO combinations, are effective treatments for patients with advanced HCC

  • Survival analysis for IO treatment shifts from median overall survival (OS) to landmark analysis

  • IO and IO combinations may result in inflammatory side effects, known as irAEs. Most of these AEs can be treated with steroids

  • Recognise the efficacy of IO and IO combinations 
    • Understand the survival curve when assessing IO treatment 
    • Know the place of IO and IO combinations in the treatment landscape for patients with HCC 
  • Recognise the immune-related adverse events (irAEs), and potential additive or synergistic toxicities associated with IO combinations 
    • Know how to early identify and manage these AEs 
  • Be able to implement IO treatments for patients with HCC in clinical practice 

Aiwu Ruth He, MD, PhD is a Professor of Medicine at Columbia University Medical Center. She earned her MD from the Xiangya School of Medicine at Central South University and her PhD in Biochemistry from East Carolina University’s Brody School of Medicine. Dr He completed her postdoctoral training at the National Institutes of Health under the mentorship of Dr Simeon Taylor, followed by an internal medicine residency at the Brody School of Medicine and a Hematology/Oncology fellowship at Georgetown University Hospital.

 

Dr He is a recognized leader in liver cancer research and patient care, with a primary focus on developing innovative therapeutics for hepatocellular carcinoma (HCC) and biliary tract cancer (BTC). 

 

She is deeply committed to a programmatic, multidisciplinary approach to clinical practice, ensuring optimal outcomes for her patients across the continuum of care.

 

Outside of her clinical duties, Dr He serves as the Director of Hepatobiliary Cancers in the Department of Medicine, Division of Hematology and Oncology, as well as the Director of Liver Transplant Oncology at the Center for Liver Disease and Transplantation. In these roles, she oversees clinical research on hepatobiliary cancers.

 

For a list of publications, please visit:

https://pubmed.ncbi.nlm.nih.gov/?term=he%2C+AR+or+He%2C+aiwu

Prof. Aiwu Ruth He has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, BMS, Boston Scientific, Eisai, Genentech and Merck.
Programme summary
Take the micro learning now
Other episodes of this series
The Use of Immunotherapy in HCC

The Use of Immunotherapy in HCC

Module 1: Efficacy and Safety

 Current Module
The Use of Immunotherapy in HCC

The Use of Immunotherapy in HCC

Module 2: In-depth Subgroup Analyses and Challenges
The expanding role of immunotherapy in HCC

The expanding role of immunotherapy in HCC

Module 3: Combining locoregional and systemic treatments in intermediate HCC
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO 
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Endorsement
AASLD
Digestive Cancers Europe
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved
Programme summary
  • clock Duration MIN
  • clock Language(s) flag
Other episodes of this series
The Use of Immunotherapy in HCC

The Use of Immunotherapy in HCC

Module 1: Efficacy and Safety

 Current Module
The Use of Immunotherapy in HCC

The Use of Immunotherapy in HCC

Module 2: In-depth Subgroup Analyses and Challenges
The expanding role of immunotherapy in HCC

The expanding role of immunotherapy in HCC

Module 3: Combining locoregional and systemic treatments in intermediate HCC
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO 
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Endorsement
AASLD
Digestive Cancers Europe
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

eks
EKS / On-demand webinar
Oncology 
Multiple Myeloma: Is it time to rethink how we sequence treatments?

On-demand materials from an Experts Knowledge Share event

Experts
Prof. Karthik Ramasamy, Dr Joshua Richter, Dr Faisal Basheer, Dr Andrew Charlton
  • download Downloadable
    Resources
  • clock 80 MIN
  • calendar Mar 2026
COR2ED
This programme has been sponsored by Menarini Stemline and is intended for HCPs in the UK only    MAT-GB-SEL-00774
conference-update Conference update

Episode

2

of 2

episode
Oncology Rare diseases Endocrinology 
Actualités du Congrès l’ENETS 2026

Points de vue d’experts sur les dernières données concernant le cancer neuroendocrinien

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education
NET CONNECT
Cette vidéo est soutenue par une subvention indépendante à visée éducative d’Ipsen.  Les contenus publiés sur ce site internet sont sous la responsabilité de leurs auteurs. Certaines données scientifiques publiées sur ce site sont susceptibles de ne pas être validées par la commission d’Autorisation de Mise sur le Marché, et ne doivent pas être mises en pratique. Elles doivent être lues et comprises avec le plus grand discernement et sont données dans leur cadre de la diffusion de l’information sur l’état actuel de la recherche auprès de la communauté scientifique internationale  
conference-update Conference update

Episode

1

of 2

episode
Oncology Rare diseases Endocrinology 
Update from ENETS 2026

Experts share their views on latest data in neuroendocrine cancer

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education
NET CONNECT
This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
patient-support Patient Support
Oncology Hemato-oncology Pediatrics 
Personalised treatment in childhood cancer: A journey through NTRK fusion testing

Experts
Linet Menachery
Endorsed by
NTRKers ICAN international cancer advocacy network Biomarker Collaborative
  • clock 4 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education
PRECISION ONCOLOGY CONNECT
Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology 
Update from ESGO 2026 – PYNNACLE Phase 2 study: Interim results from the ovarian cancer cohort

Clinical insights and expert discussion

Experts
Prof. Domenica Lorusso, Prof. Jean-Sebastien Frenel
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Mar 2026
COR2ED
This programme has been sponsored by PMV Pharma and is intended for HCPs only.
Explore all programmes